Stock listing

ASX:PYC PYC Therapeutics Limited Share Price

Home listing (ASX) of PYC Therapeutics Limited

Follow PYC Therapeutics Limited into a list and get an email when it puts out news.

Share price · ASX:PYC

$1.65 AUD -0.09 (-5.2%)

Close on Nov 20, 2026

Past year +22.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.60 – $1.67 AUDNov 20, 2026
Volume
5.10M sharesNov 20, 2026
Market cap
$1.62B AUDAt the close on Nov 20, 2026 · price × 984.2M shares outstanding
52-week range
$1.05 – $2.93 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$9.49M AUDMedian day 2.87M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
PYC Therapeutics Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:PYC · Home$1.645 AUD-0.09 (-5.2%)5,097,493$1.625$1.673$1.598$1.735Close on Nov 20, 2026
OTC:PYCXF$1.219 USD-0.031 (-2.5%)900$1.219$1.219$1.219$1.25Close on Nov 13, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:PYC · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.645-0.09-5.2%$1.625$1.673$1.5985,097,493
$1.735+0.01+0.6%$1.735$1.80$1.7152,852,169
$1.725-0.065-3.6%$1.77$1.81$1.6783,427,933
$1.79-0.045-2.5%$1.86$1.86$1.7752,047,132
$1.835-0.08-4.2%$1.90$1.915$1.822,539,508
$1.915+0.01+0.5%$1.905$1.955$1.862,258,949
$1.905-0.09-4.5%$1.97$1.97$1.9032,577,728
$1.995+0.005+0.3%$1.99$2.04$1.913,635,539
$1.99+0.11+5.9%$1.87$2.01$1.8651,771,481
$1.88-0.05-2.6%$1.84$1.925$1.7882,388,206
$1.93+0.08+4.3%$1.92$1.96$1.883,999,324
$1.85+0.05+2.8%$1.775$1.885$1.773,924,895
$1.80-0.10-5.3%$1.845$1.875$1.7582,585,037
$1.90+0.02+1.1%$1.87$2.00$1.842,774,166
$1.88-0.055-2.8%$1.93$1.93$1.8554,194,530
$1.935-0.035-1.8%$1.975$1.993$1.912,878,124
$1.97+0.05+2.6%$1.93$2.005$1.9053,130,589
$1.92+0.165+9.4%$1.75$1.93$1.754,365,632
$1.755-0.025-1.4%$1.75$1.78$1.7154,563,687
$1.78-0.03-1.7%$1.83$1.83$1.7032,890,704
$1.81+0.01+0.6%$1.82$1.83$1.761,956,748
$1.80+0.02+1.1%$1.805$1.84$1.7352,099,987
$1.78-0.03-1.7%$1.83$1.83$1.7352,566,944
$1.81-0.10-5.2%$1.88$1.895$1.7921,938,021
$1.91+0.06+3.2%$1.86$1.915$1.792,442,045
$1.85-0.13-6.6%$1.96$1.96$1.803,402,571
$1.98-0.16-7.5%$2.05$2.11$1.9753,435,658
$2.14-0.25-10.5%$2.36$2.39$2.114,108,882
$2.39-0.06-2.4%$2.45$2.51$2.392,192,220
$2.45-0.08-3.2%$2.52$2.52$2.392,689,888
$2.53+0.06+2.4%$2.49$2.54$2.4252,601,344
$2.47-0.21-7.8%$2.70$2.73$2.467,175,628
$2.68+0.13+5.1%$2.60$2.71$2.593,075,321
$2.55+0.09+3.7%$2.47$2.63$2.441,367,849
$2.46-0.05-2.0%$2.55$2.56$2.441,219,518
$2.51-0.17-6.3%$2.66$2.67$2.491,677,046
$2.68-0.09-3.2%$2.80$2.815$2.673,741,769
$2.77+0.02+0.7%$2.75$2.84$2.743,147,785
$2.75-0.07-2.5%$2.80$2.80$2.702,130,618
$2.82-0.09-3.1%$2.83$2.87$2.801,207,356
$2.91+0.07+2.5%$2.78$2.91$2.788,402,265
$2.84-0.04-1.4%$2.87$2.88$2.751,849,823
$2.88+0.09+3.2%$2.83$2.90$2.7255,477,742
$2.79+0.12+4.5%$2.58$2.93$2.588,163,885
$2.67+0.27+11.3%$2.43$2.67$2.4251,841,254
$2.40+0.15+6.7%$2.25$2.40$2.202,866,025
$2.25-0.01-0.4%$2.34$2.35$2.231,772,350
$2.26+0.03+1.3%$2.27$2.31$2.234,137,330
$2.23-0.07-3.0%$2.30$2.30$2.192,889,364
$2.30-0.02-0.9%$2.32$2.34$2.263,180,085
$2.32-0.10-4.1%$2.44$2.46$2.292,663,026
$2.42-0.08-3.2%$2.48$2.50$2.414,360,668
$2.50-0.01-0.4%$2.51$2.54$2.463,014,564
$2.51+0.02+0.8%$2.59$2.60$2.4653,301,375
$2.49-0.08-3.1%$2.58$2.59$2.473,347,904
$2.57+0.14+5.8%$2.45$2.62$2.433,992,122
$2.43+0.14+6.1%$2.30$2.43$2.2710,751,807
$2.29-0.03-1.3%$2.32$2.35$2.277,476,947
$2.32+0.07+3.1%$2.30$2.32$2.218,641,108
$2.25-0.01-0.4%$2.21$2.31$2.201,548,143
$2.26+0.09+4.1%$2.20$2.28$2.112,391,608
$2.17+0.09+4.3%$2.10$2.19$2.091,360,907
$2.08-0.02-1.0%$2.09$2.105$2.041,361,994
$2.10+0.03+1.4%$2.10$2.15$2.052,019,395
$2.07-0.13-5.9%$2.19$2.20$2.052,827,588
$2.20+0.05+2.3%$2.16$2.225$2.151,520,843

Splits

3 splits since 2019 · ASX:PYC · every price before a split is adjusted for it

DayRatioWhat
85-for-83Split
1-for-10Consolidation
53-for-52Split
Ticker
ASX:PYC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

PKD Program - Enrolment Target Met

Nov 12, 2026

Closed $1.84 (-4.2%) on Nov 13, 2026

Results of Annual General Meeting

Nov 11, 2026

Closed $1.92 (+0.5%) on Nov 12, 2026

Change of Director's Interest Notice

Nov 5, 2026

Closed $1.88 (-2.6%) on Nov 6, 2026

Annual General Meeting - Conference Link

Nov 4, 2026

Closed $1.93 (+4.3%) on Nov 5, 2026

Exercise of Options and Cleansing Notice

Oct 29, 2026

Closed $1.88 (-2.8%) on Oct 30, 2026

PKD Program - ASN Presentation

Oct 22, 2026

Closed $1.78 (-1.7%) on Oct 23, 2026

All PYC Therapeutics Limited news

PYC Therapeutics Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
49 in the last 12 months · 284 in all · newest Nov 12, 2026 · oldest 2016
Decks
102 decks · latest Nov 12, 2026

Where PYC Therapeutics Limited is listed

ListingExchangeCountryCurrency
ASX:PYC · Home listing · This pageASXAustraliaAUD
OTC:PYCXFOTCUnited StatesUSD

Valuation

Price/book 2.3× against a median of 4.5×: 4th lowest of 11 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$1.17B AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
PYC Therapeutics Limited · ASX:PYCUS$1.07BUS$775.8Mn/an/an/a2.3×n/a0.0×n/a
Ascentage Pharma Group International · HKEX:6855US$1.11BUS$1.14Bn/a13.7×n/a13.4×−216.5%3.8×n/a
Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321US$1.10BUS$1.10B102×6.8×n/a2.9×6.6%0.5×n/a
Pharma Mar SA · BME:PHMUS$1.10BUS$978.5M14.6×3.8×16.6×4.2×28.8%0.3×n/a
Alpha Tau Medical Ltd · NASDAQ:DRTSUS$1.09BUS$1.00Bn/an/an/a55.3×n/a0.8×1.89
Kardigan, Inc. · NASDAQ:KARDUS$1.08BUS$621.1Mn/an/an/a1.9×n/a0.0×n/a
Jade Biosciences, Inc. · NASDAQ:JBIOUS$1.06BUS$583.6Mn/an/an/a2.3×n/a0.0×1.14
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062US$1.02BUS$984.8Mn/a9.2×n/a9.5×−146.4%2.9×n/a
SpyGlass Pharma, Inc. · NASDAQ:SGPUS$1.02BUS$809.5Mn/an/an/a4.8×n/a0.0×1.01
Median of the othersUS$1.07BUS$981.7M58.5×9.3×16.6×4.5×−137.6%0.4×1.21

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
4.07 AUD · Analysts' mean
EPS, year to Jun 2027
-0.082 · 5 analysts

Team and board

Officers

OfficerRole
Rohan HockingsExecutive Director & Chief Executive Officer
Thomas UlmerChief Financial Officer
Garrett BrayChief Operating Officer
Jonathan RileyGeneral Counsel
Candice JungeChief Clinical Development Officer
Janya GrainokChief Scientific Officer
Paula CunninghamChief Development Officer

Board

DirectorRole
Peter ColemanIndependent Non-Executive Chair
Ian ConstableNon-Executive Director
Rohan HockingsExecutive Director & Chief Executive Officer

Events

QuarterResultsShare move
Q4 2025Aug 27, 2025 · Before open−0.4%
Q2 2025Feb 27, 2025+2.9%
Q2 2023Feb 28, 2023 · After close+2.6%
Q4 2022Sep 23, 2022 · Before open−3.9%
Q2 2022Feb 28, 2022−2.9%
Q4 2021Aug 31, 2021+3.3%
Q2 2021Feb 26, 2021+3.6%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (November 2026)Shareholder meeting37 slidesNov 12, 2026
American Society of Nephrology (ASN) Kidney Week 2026Conference14 slidesOct 23, 2026
EURetina 2026Conference19 slidesOct 2, 2026
Investor Presentation (September 2026)Investor deck17 slidesSep 4, 2026
Neuro-Ophthalmology Society of Australia (NOSA) Annual Scientific Meeting 2026Conference16 slidesSep 3, 2026
2026 PMS Foundation Family ConferenceConference19 slidesJul 20, 2026
Corporate Update (May 2026)Corporate update19 slidesMay 22, 2026
ARVO 2026Conference70 slidesMay 4, 2026
North American Neuro-Ophthalmology Society (NANOS) 2026 ConferenceConference16 slidesMar 24, 2026
Investor Presentation (February 2026)Investor deck65 slidesFeb 2, 2026
Show 50 decks
DeckKindSlidesDate
44th annual JP Morgan Healthcare Conference 2026Conference40 slidesJan 13, 2026
Investor Presentation (January 2026)Investor deck38 slidesJanuary 2026
Shareholder Meeting (November 2025)Shareholder meeting10 slidesNov 18, 2025
Investor Presentation (October 2025)Investor deck6 slidesOct 13, 2025
Technical Presentation (August 2025)Technical16 slidesAug 29, 2025
Corporate Update (August 2025)Corporate update25 slidesAug 1, 2025
Investor Presentation (May 2025)Investor deck13 slidesMay 30, 2025
Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2025Conference25 slidesMay 2, 2025
Retinal Therapeutics Innovation Summit (May 2025)Conference23 slidesMay 2, 2025
Investor Presentation (March 2025)Investor deck21 slidesMar 28, 2025
Investor Presentation (February 2025)Investor deck36 slidesFeb 17, 2025
Investor Presentation (November 2024)Investor deck12 slidesNov 28, 2024
Technical Presentation (November 2024)Technical17 slidesNov 22, 2024
Shareholder Meeting (November 2024)Shareholder meeting16 slidesNov 13, 2024
E&P Healthcare Conference 2024Conference9 slidesSep 26, 2024
Corporate Update (August 2024)Corporate update23 slidesAug 30, 2024
Canaccord Genuity Growth Conference 2024Conference15 slidesAug 13, 2024
Bioshares Biotech Summit 2024Conference21 slidesJul 12, 2024
Corporate Update (May 2024)Corporate update14 slidesMay 9, 2024
ARVO 2024Conference17 slidesMay 6, 2024
ARVO 2024 (Association for Research in Vision and Ophthalmology)Conference20 slidesMay 6, 2024
Investor Presentation (March 2024)Investor deck41 slidesMar 14, 2024
Euroz Hartleys Healthcare Conference 2024Conference12 slidesFeb 6, 2024
Investor Presentation (February 2024)Investor deck8 slidesFeb 2, 2024
Shareholder Meeting (November 2023)Shareholder meeting9 slidesNov 24, 2023
Investor Presentation (November 2023)Investor deck21 slidesNov 17, 2023
Wilsons Drug & Device Conference 2023Conference13 slidesOct 26, 2023
Corporate Update (October 2023)Corporate update17 slidesOct 5, 2023
Q3 2023 Earnings PresentationEarnings9 slidesSep 27, 2023
E&P Healthcare Conference 2023Conference14 slidesSep 12, 2023
Investor Presentation (June 2023)Investor deck19 slidesJun 16, 2023
BIO International Convention 2023Conference15 slidesJun 6, 2023
BIO 2023Conference31 slidesApr 19, 2023
Investor Presentation (February 2023)Investor deck21 slidesFeb 17, 2023
Investor Presentation (February 2023)Investor deck37 slidesFeb 3, 2023
Shareholder Meeting (November 2022)Shareholder meeting17 slidesNov 23, 2022
Shareholder Meeting (November 2022)Shareholder meeting17 slidesNov 23, 2022
Investor Presentation (May 2022)Investor deck18 slidesMay 31, 2022
Q1 2022 Earnings PresentationEarnings7 slidesMar 17, 2022
Shareholder Meeting (November 2021)Shareholder meeting13 slidesNov 18, 2021

This page holds 50 of 102 decks. Open Decks

Open Decks

Financings

RaiseDateIn US dollars
Rights offering of new fully paid ordinary shares (retail entitlement offer)
Closed: A$47M in the latest tranche · A$1.5 a share · E&P Capital Pty Ltd +2
Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Bloom Burton Securities Inc. (co-lead)
Use of proceeds: Advance PYC-003, PYC-002, VP-001 and PYC-001 drug candidates toward registrational or first-in-human trials, plus working capital, R&D and costs
Mar 4, 2026
Private placement of fully paid ordinary shares
Closed: A$128M raised · A$1.5 a share · Bloom Burton Securities Inc.
Dealers: Bloom Burton Securities Inc. (lead)
Buyers: RA Capital Management; Perceptive Advisors; Driehaus Capital Management; MPM BioImpact; Rock Springs Capital; RTW Investments
Use of proceeds: Extend cash runway through CY2030 to deliver human safety and efficacy data for all four drug development programs
Feb 4, 2026US$89.6M
Rights offering of new fully paid ordinary shares
Announced: about A$145.8M · A$1.25 a share · E&P Capital Pty Ltd +6
Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Custom Binders Pty Ltd, John Baird, Sami Zouad, Adrian Bonaddio, Dr Yang Sheng Yeo & Ms Esther Mei Yen Liaw as trustees for the Papy Family Trust
Buyers: Alan Tribe (intends to subscribe for New Shares with a value of A$35 million)
Insiders: Chairman Alan Tribe, holding 34% of shares, intends to subscribe for New Shares with a value of A$35 million
Use of proceeds: Advance blinding eye disease, polycystic kidney disease and Phelan-McDermid Syndrome drug candidates through human trials; working capital and offer costs
Feb 17, 2025US$92.69M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue23.5M22.1M15.8M16.0M3.07M2.40M25048.5K2.76M
Cost of revenue1.20M1.12M1.07M882.0K839.5K622.4K547.1K130.6K81.3K4.67M
Gross profit-1.20M23.5M22.1M14.9M15.2M2.45M1.85M-130.6K-32.8K-1.91M
Research and development74.0M70.1M56.4M35.1M24.0M14.0M5.88M4.51M6.96M4.67M
Selling, general and administrative6.69M7.07M4.51M4.09M6.30M7.83M3.82M409.8K1.16M1.04M
Operating income-82.7M-53.6M-38.9M-39.2M-30.2M-21.8M-9.70M-7.10M-9.77M-4.25M
Depreciation and amortization1.20M1.12M1.07M882.0K839.5K622.4K547.1K130.6K81.3K55.3K
EBITDA-81.5M-52.5M-37.8M-38.3M-29.4M-21.2M-9.15M-6.97M-9.69M-4.20M
Interest expense40.5K62.2K49.2K27.3K32.6K38.8K42.9K118.2K00
Income before tax-69.8M-51.0M-55.7M-39.2M-30.3M-21.7M-9.48M-6.98M-9.60M-4.18M
Income tax-26.0M-23.5M-17.6M-15.8M-16.0M-3.07M-2.40M-2.90M-2.17M-2.22M
Net income-43.3M-50.3M-37.7M-22.8M-13.9M-17.8M-6.82M-4.08M-7.43M-1.95M
Earnings per share, basic-0.06-0.10-0.01-0.01-0.00-0.01-0.00-0.00-0.00-0.00

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents53.6M153.1M66.9M15.6M29.1M18.4M7.24M1.66M3.15M9.94M
Short-term investments394.0M033.1M18.2M4.52M
Receivables34.1M24.1M18.0M16.3M10.1M185.6K82.7K10.8K18.5K192.2K
Inventory-18.0M-42.7K-10.8K-192.2K
Current assets482.2M177.5M85.6M31.9M39.2M51.8M25.6M6.22M3.28M10.1M
Property, plant and equipment1.90M1.57M1.04M1.63M1.49M1.14M482.9K143.4K216.1K
Total assets708.5M183.3M91.2M37.2M45.4M57.9M31.5M6.70M3.42M10.3M
Accounts payable9.89M8.75M7.53M4.92M2.57M2.35M97.3K193.7K1.68M1.45M
Current liabilities14.4M12.3M9.11M8.41M4.39M3.30M705.6K401.9K1.77M1.49M
Total debt625.0K1.02M1.11M315.5K943.8K730.4K798.1K798.1K
Total liabilities15.2M13.3M10.2M8.72M5.15M4.02M1.35M401.9K1.77M1.49M
Shareholders' equity693.3M169.6M80.5M27.7M39.4M53.0M28.5M6.30M1.65M8.86M
Shares outstanding732.6M500.5M3.94B3.25B3.22B3.13B2.80B2.80B2.22B2.01B

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-44.5M-51.6M-38.6M-24.4M-21.8M-11.8M-5.75M-5.13M-6.71M-1.88M
Capital spending-531.4K-975.4K-307.0K-491.1K-386.9K-591.0K-106.1K-457.5K-210.6K-4.54K
Free cash flow-45.1M-52.5M-38.9M-24.9M-22.2M-12.4M-5.85M-5.58M-6.92M-1.89M
Cash from investing-616.2M-975.4K-307.0K-477.1K32.7M-15.5M-13.8M-4.98M-210.6K-3.46K
Cash from financing563.2M138.7M90.2M11.4M-182.4K38.6M25.1M8.62M125.2K4.75M
Dividends paid-10.5M-36.3M-23.5M
Share buybacks-36.6M-6.80M-1.57M-976.2K-976.2K-2.29M-1.62M-503.2K-9.82K-313.3K
Change in cash-99.5M86.2M51.3M-13.5M10.7M11.2M1.06M-1.49M-6.79M2.87M

Open Financials

Filings

FilingDateTypeFiled with
PKD Program - Enrolment Target MetNov 12, 2026Other filingsASX
Results of Annual General MeetingNov 11, 2026Meeting outcomeASX
2026 Annual General Meeting Program and CEO PresentationNov 11, 2026Meeting noticeASX
Notification regarding unquoted securities - PYCNov 9, 2026Other filingsASX
Change of Director's Interest NoticeNov 5, 2026Ownership change noticeASX
Annual General Meeting - Conference LinkNov 4, 2026Meeting noticeASX
Change of Director's Interest NoticeNov 3, 2026Ownership change noticeASX
Change of Director's Interest NoticeOct 30, 2026Ownership change noticeASX
Exercise of Options and Cleansing NoticeOct 29, 2026FinancingASX
Application for quotation of securities - PYCOct 29, 2026FinancingASX
Show 200 filings
FilingDateTypeFiled with
Quarterly Activities/Appendix 4C Cash Flow ReportOct 28, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 28, 2026Quarterly reportASX
PKD Program - ASN PresentationOct 22, 2026Operations updateASX
Exercise of Options and Cleansing NoticeOct 15, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 11, 2026Meeting noticeASX
Application for quotation of securities - PYCOct 7, 2026FinancingASX
Notification of cessation of securities - PYCOct 7, 2026FinancingASX
PKD Program - Presentation of Data at ASN ConferenceOct 6, 2026Operations updateASX
RP11 PROGRAM - PRESENTATION AT EURETINA 2026Oct 1, 2026Other filingsASX
PKD - First Patient Dosed in OLE StudySep 10, 2026Operations updateASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
Investor Webinar Presentation Q3 2026Sep 3, 2026Other filingsASX
ADOA Program - Data PresentationSep 2, 2026Other filingsASX
Ceasing to be a substantial holderSep 2, 2026Ownership change noticeASX
PKD - Presentation of Clinical Safety DataAug 30, 2026Other filingsASX
2026 Corporate Governance StatementAug 28, 2026Other filingsASX
Appendix 4GAug 28, 2026Other filingsASX
2026 Annual Report to ShareholdersAug 28, 2026Annual reportASX
Appendix 4EAug 28, 2026ResultsASX
Notification regarding unquoted securities - PYCAug 26, 2026Other filingsASX
Investor WebinarAug 17, 2026Other filingsASX
Change of Director's Interest NoticeAug 13, 2026Ownership change noticeASX
Notification regarding unquoted securities - PYCAug 13, 2026Other filingsASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 28, 2026Quarterly reportASX
PKD - Safety Committee Approves Dose EscalationJul 21, 2026Other filingsASX
ADOA Program UpdateJul 20, 2026Other filingsASX
PKD - Initiation of Multiple Dose Clinical TrialMay 6, 2026Other filingsASX
Presentation of Ophthalmology Clinical Trial Data at ARVOMay 3, 2026Operations updateASX
ADOA Program - SRC Approve Progression to Multi-Dose StudyApr 15, 2026Other filingsASX
Completion of Retail Entitlement OfferMar 3, 2026FinancingASX
PKD Clinical Trial - Approval to Escalate DosingFeb 26, 2026Operations updateASX
Half Yearly Report and AccountsFeb 23, 2026Interim reportASX
Retail Offer BookletFeb 8, 2026Offer documentASX
Completion of Placement and Institutional Entitlement OfferFeb 3, 2026FinancingASX
PYC Raising up to $653m to Deliver Human Efficacy DataFeb 1, 2026FinancingASX
PYC Capital Raising PresentationFeb 1, 2026Offer documentASX
Trading HaltFeb 1, 2026Trading halt or suspensionASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 22, 2026Quarterly reportASX
PKD Clinical Trial - Safety Outcomes in Part ADec 18, 2025Operations updateASX
Sustained Vision Improvement in RP11 PatientsNov 13, 2025Operations updateASX
ADOA Program Initiation of Global Repeat Dose StudyOct 20, 2025Other filingsASX
PMS Program Data Supports Progression to Human TrialsOct 12, 2025Other filingsASX
ADOA Program Progressing to Multiple Dose StudyOct 8, 2025Other filingsASX
Board and Management ChangesSep 21, 2025Management or board changeASX
Correction to Trading Halt RequestSep 19, 2025Trading halt or suspensionASX
Change of Managing DirectorSep 16, 2025Management or board changeASX
ADOA Program - Presentation of Clinical Data at NOSA 2025Sep 4, 2025Other filingsASX
PKD Program - Presentation of Safety Data at ANZSNAug 28, 2025Other filingsASX
Appendix 4EAug 28, 2025ResultsASX
Approval to Escalate Dosing in Kidney Disease Clinical TrialAug 7, 2025Operations updateASX
Approval to Progress Kidney Disease Trial to Next StageJul 6, 2025Operations updateASX
Fourth Drug Program Progressing to Human TrialsJun 26, 2025Other filingsASX
FDA Alignment on Registrational Trial Design RP11 ProgramJun 22, 2025Other filingsASX
SRC Approves Dose Escalation in ADOA Clinical TrialJun 10, 2025Other filingsASX
Approval to Escalate Dosing in Kidney Disease TrialMay 25, 2025Operations updateASX
Presentation of Clinical Proof of Concept in Lead ProgramApr 27, 2025Other filingsASX
Completion of Entitlement OfferApr 16, 2025FinancingASX
First Subject Dosed in PKD Clinical TrialApr 9, 2025Other filingsASX
Placement of ShortfallApr 9, 2025FinancingASX
Retail Entitlement Offer BookletFeb 24, 2025Offer documentASX
Completion of Institutional Entitlement OfferFeb 18, 2025FinancingASX
PYC Equity Raising PresentationFeb 16, 2025Offer documentASX
PYC Equity Raising to Raise up to $146 MillionFeb 16, 2025FinancingASX
Approval to Commence Human Trials in Kidney ProgramFeb 9, 2025Other filingsASX
ADOA Safety Review Committee Approves Dose EscalationJan 30, 2025Operations updateASX
US FDA Grants Rare Pediatric Disease Designation to VP-001Jan 19, 2025Other filingsASX
PYC Nominates Fourth Clinical Drug Candidate in PMS ProgramDec 15, 2024Other filingsASX
PYC to Progress Kidney Drug Candidate Into Human TrialsNov 26, 2024Other filingsASX
Consolidation/Split - PYCNov 11, 2024Other filingsASX
RP11 SRC Approves Dose Escalation to Final Patient CohortNov 4, 2024Other filingsASX
First ADOA Patient Dosed in Clinical TrialOct 31, 2024Other filingsASX
Interim Update on Progress in RP11 Repeat Dose TrialsOct 21, 2024Interim reportASX
US FDA Grants Orphan Drug Designation to PYC Drug CandidateOct 20, 2024Other filingsASX
Notice of Annual General Meeting/Proxy FormOct 14, 2024Meeting noticeASX
FDA Grants Rare Pediatric Disease Designation to PYC-001Aug 29, 2024Other filingsASX
Appendix 4E and Audited Financial StatementsAug 29, 2024ResultsASX
PYC to Start Human Trials in Second Blinding Eye DiseaseAug 14, 2024Other filingsASX
Visual Improvement in Multiple RP11 PatientsAug 11, 2024Other filingsASX
RP11 Clinical Trial Update - AmendedAug 5, 2024Other filingsASX
RP11 Clinical Trial UpdateAug 4, 2024Operations updateASX
Extension of RP11 Single Dose Study Into Multiple Dose StudyJul 22, 2024Operations updateASX
Initial Dosing Completed in Cohort 1 of RP11 MAD StudyJul 16, 2024Operations updateASX
Commencement of RP11 Multiple Dose TrialJul 9, 2024Operations updateASX
RP11 Drug Candidate Safe and Well ToleratedJun 30, 2024Other filingsASX
PMS Drug Candidate Effective In Human Brain CellsJun 6, 2024Operations updateASX
RP11 Clinical Trial Dosing Completed in Cohort 4May 15, 2024Operations updateASX
Successful GLP Tox Studies in Second Blinding Eye DiseaseMay 13, 2024Operations updateASX
Presentation of RP11 Clinical Trial Data at ARVO ConferenceMay 5, 2024Other filingsASX
RP11 Drug Candidate Progressing to Mid-Stage Human TrialsApr 28, 2024Other filingsASX
Kidney Disease Drug Candidate Progressing to Human TrialsApr 21, 2024Operations updateASX
$74.6 Million Extension of Cash RunwayApr 10, 2024FinancingASX
PYC Equity Raising to Raise up to $74.6 MillionMar 13, 2024FinancingASX
RP11 Clinical Trial - Dosing Completed in Cohort 3Feb 27, 2024Operations updateASX
Receipt of $4.5m Collaboration FeeFeb 16, 2024Other filingsASX
AI Driven Drug Discovery Collaboration with Google CloudJan 1, 2024Operations updateASX
RP11 Clinical Trial Progressing To High Dose CohortDec 17, 2023Other filingsASX
Response to Price QueryNov 30, 2023Explanation requestASX
Supplementary InformationNov 16, 2023Other filingsASX
New Drug For Major Kidney Disease Effective In Human ModelsNov 12, 2023Other filingsASX
PYC and FDA Align On Clinical Trial Pathway in ADOANov 5, 2023Operations updateASX
RP11 Clinical Trial Dosing Completed In Patient Cohort 2Nov 2, 2023Operations updateASX
PYC-001 Effective In Both NHPs and Patient-Derived ModelsOct 3, 2023Other filingsASX
Safety Review Committee Approves Dose EscalationSep 21, 2023Other filingsASX
RP11 Clinical Trial Dosing Completed In Patient Cohort 1Aug 17, 2023Other filingsASX
PYC Increases Ownership of VP-001 ProgramAug 9, 2023Other filingsASX
PYC Receives FDA Fast Track DesignationAug 1, 2023Other filingsASX
Successful Toxicology Results Pave Way for Phase 2 TrialJul 17, 2023Other filingsASX
FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIALJun 29, 2023Other filingsASX
Placement Supporting DocumentMay 11, 2023FinancingASX
Successful Completion of $30m PlacementMay 10, 2023FinancingASX
Commencement of First Clinical Study in RP11Apr 25, 2023Other filingsASX
Second Drug Program Progressing to Human TrialsApr 3, 2023Other filingsASX
FDA Clears PYC to Commence First Human Trials in RP11Mar 5, 2023Other filingsASX
VP-001 IND LodgementFeb 1, 2023Other filingsASX
Successful Toxicology Studies Pave Way for Human TrialsNov 6, 2022Other filingsASX
Central Nervous System Drug Program Added to PYC PipelineSep 26, 2022Other filingsASX
Preliminary Final ReportAug 30, 2022ResultsASX
PYC Increases Shareholding in Vision PharmaFeb 16, 2022Other filingsASX
Quarterly Activities and Appendix 4C Cash Flow ReportJan 26, 2022Quarterly reportASX
Successful Completion of Key Translational MilestoneNov 15, 2021Other filingsASX
Retina Target Engagement Confirmed in Large EyeSep 29, 2021Other filingsASX
Second Drug Program Progressing Towards Human TrialsJun 8, 2021Other filingsASX
March 2021 Quarterly Report and CashflowApr 29, 2021Quarterly reportASX
Lead Investigational Drug Demonstrates Key ImprovementMar 1, 2021Legal or regulatory actionASX
Half Year Accounts and Appendix 4DFeb 26, 2021Interim reportASX
Progress US Clinical Stage Company and Corporate ObjectivesFeb 21, 2021Other filingsASX
Quarterly Activities Report and Appendix 4CJan 29, 2021Quarterly reportASX
Visual Evidence of Lead Drugs EfficacyDec 15, 2020Other filingsASX
Review of Activities and Appendix 4COct 26, 2020Quarterly reportASX
Successful Institutional Entitlement Offer and PlacementOct 21, 2020FinancingASX
PYC Business and Equity Raising PresentationOct 19, 2020Other filingsASX
PYC Equity Raising to Raise up to $55 MillionOct 19, 2020Other filingsASX
New Drug for Substantial Unmet Need Added to PipelineOct 11, 2020Other filingsASX
PYCs Lead Drug Effective in Patient Derived Models TestedOct 6, 2020Other filingsASX
Second Potential Blockbuster Drug Added to PYCs PipelineOct 4, 2020Other filingsASX
Creation of Novel Gene Therapy Delivery TechnologySep 7, 2020Other filingsASX
Appendix 4E Preliminary Final ReportAug 31, 2020ResultsASX
Executive re-structure across global operationsAug 19, 2020Other filingsASX
Shareholder Update - Forward View 2020 MilestonesAug 4, 2020Other filingsASX
June 2020 Quarterly Activity Report and CashflowJul 30, 2020Other filingsASX
Successful Dose Response & Toxicity Studies in Lead ProgramJul 21, 2020Other filingsASX
S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020Other filingsASX
March 2020 Quarterly Activities and Cash Flow ReportApr 29, 2020Quarterly reportASX
Successful Efficacy Result on Path to First in Human StudiesMar 31, 2020Other filingsASX
Investor Presentation - February 2020Feb 23, 2020Other filingsASX
CEO Appointment and Establishment of US OfficeFeb 12, 2020Other filingsASX
Expansion Of Drug Development PipelineFeb 2, 2020Other filingsASX
Appendix 4C - quarterlyJan 31, 2020Quarterly reportASX
Quarterly Shareholder UpdateJan 5, 2020Other filingsASX
Drug Delivery Greater Than 100% More Effective In AnimalsDec 1, 2019Other filingsASX
Conclusion of Genentech Antimicrobial CollaborationNov 14, 2019Other filingsASX
Retail Offer DocumentNov 3, 2019Offer documentASX
PYCs Institutional Entitlement Offer ClosesNov 3, 2019FinancingASX
Entitlement Offer - Investor PresentationOct 31, 2019FinancingASX
$26.8m Fully Underwritten Accelerated Entitlement OfferOct 30, 2019FinancingASX
Sept 2019 Quarterly Shareholder Update and Appendix 4COct 30, 2019Quarterly reportASX
Successful Major Milestone - Human Retina in a Dish ModelsOct 8, 2019Other filingsASX
Strategic Partnership and Lead ProgramOct 1, 2019Other filingsASX
Successful Time-Course Studies in AnimalsSep 25, 2019Other filingsASX
Successful Competitive Drug Evaluation in AnimalsSep 2, 2019Other filingsASX
Successful Time - Course Studies in AnimalsAug 22, 2019Other filingsASX
Response to ASX Aware QueryAug 7, 2019Explanation requestASX
Phylogicas Technology is Effective in Human CellsAug 6, 2019Other filingsASX
Company Presentation - July 2019Jul 23, 2019Other filingsASX
Operational Update and Appendix 4CJul 23, 2019Quarterly reportASX
Animal Models - 400% Outperformance of Gold StandardJul 22, 2019Other filingsASX
Break Through Animal Model ResultsJun 26, 2019Other filingsASX
March 2019 Quarterly Operational Update and App4CApr 29, 2019Other filingsASX
Collaboration Agreement - siRNA deliveryMar 13, 2019Other filingsASX
Flagship Program - Successful Animal ModelsMar 11, 2019Other filingsASX
First Competitive Read Out - Peptide VaccineFeb 8, 2019Other filingsASX
Dec 2018 Operational Update and App4CJan 31, 2019Other filingsASX
CEO letter and Operational UpdateJan 16, 2019Other filingsASX
In Vivo Success - peptide vaccine (Amended Graphics)Dec 6, 2018Other filingsASX
In vivo success - peptide vaccine in Herpes Simplex VirusDec 6, 2018Other filingsASX
Successful Delivery of CRIPR/Cas9 into Cells ex vivoDec 3, 2018Other filingsASX
FNA PresentationNov 22, 2018Other filingsASX
AGM Company PresentationNov 16, 2018Other filingsASX
Sept 2018 Quarterly Operations Update and App4COct 31, 2018Operations updateASX
Fourfold Delivery Improvement in a New Lead CandidateOct 29, 2018Other filingsASX
R&D Tax Incentive RefundOct 8, 2018Other filingsASX
Reinstatement to Official QuotationSep 11, 2018Trading halt or suspensionASX
Phylogica RecapitalisationSep 11, 2018Other filingsASX
Suspension from Official QuotationSep 10, 2018Trading halt or suspensionASX
Update on Capital RaisingSep 10, 2018FinancingASX
June 2018 Quarterly Operational Update and App4CJul 31, 2018Other filingsASX
Achievement of Major Milestone - In vivo Cre DeliveryJul 30, 2018Other filingsASX
Successful In-vivo Results Peptide Vaccine T-Cell ExpansionJul 26, 2018Other filingsASX
CEO UpdateJul 8, 2018Other filingsASX
March 2018 Operational Update and CashflowApr 30, 2018Other filingsASX

This page holds 200 of 284 filings. Open Filings

Open Filings

Cap table

Built by 6ix from PYC Therapeutics Limited’s releases · as of Mar 4, 2026

Common shares
984,210,447
Fully diluted
984,210,447

Fully diluted

LineShares
Common shares984,210,447

Share count over time

CountShares
Nov 22, 2026984,210,447

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
iShares MSCI EAFE Small-Cap ETF1.86MUS$2.22MJul 31, 2026
Vanguard Total International Stock Index Fund1.23MUS$1.46MJul 31, 2026
The Asia Pacific Small Company Series379KUS$453KJul 31, 2026
iShares Core MSCI EAFE ETF333KUS$398KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account323KUS$377KJun 30, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund315KUS$377KJul 31, 2026
iShares Core MSCI Total International Stock ETF188KUS$224KJul 31, 2026
Fidelity SAI International Small Cap Index Fund151KUS$179KJul 31, 2026
iShares Core MSCI Pacific ETF136KUS$163KJul 31, 2026
Vanguard Pacific Stock Index Fund88,701US$106KJul 31, 2026
All 13 holders
HolderSharesValueAs of
Vanguard Total World Stock Index Fund69,513US$83,005Jul 31, 2026
Dimensional International Small Cap ETF57,259US$68,367Jul 31, 2026
Dimensional VA International Small Portfolio14,590US$17,422Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Peter Coleman
Director
Buy105,820AUD 1.91AUD 202KOct 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Candice JungeChief Clinical Development Officer · Since at least Nov 5, 2026
Garrett BrayChief Operating Officer · Since at least Nov 5, 2026
Ian ConstableNon-Executive Director · Since at least Nov 5, 2026
Janya GrainokChief Scientific Officer · Since at least Nov 5, 2026
Jonathan RileyGeneral Counsel · Since at least Nov 5, 2026
Paula CunninghamChief Development Officer · Since at least Nov 5, 2026
Peter ColemanIndependent Non-Executive Chair · Since at least Nov 5, 2026
Rohan HockingsExecutive Director & Chief Executive Officer · Since at least Nov 5, 2026
Thomas UlmerChief Financial Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about PYC Therapeutics Limited.